BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Successful Beta Testing of HealthTab(TM)

Avricore Health  (TSX.V: AVCR) (OTCQB: AVCRF) today announced that patient testing has begun on the first deployment of the new HealthTab(TM)-integrated Afinion 2(TM) analyzers in the initial Shoppers Drug Mart(R) pharmacy location. This move is part of the company’s previously announced effort to screen for diabetes and cardiovascular disease, demonstrating strong demand, smooth workflow and reliable system operations. To prepare for the full public launch, a first store was selected to receive the system to begin beta-testing HealthTab(TM)’s systems, including the first patient tests. HealthTab(TM) and the instruments are performing well, demonstrating that the first installation of HealthTab(TM) with the Afinion 2(TM) analyzers is ready for prime time. “I’m so excited to have HealthTab(TM) in my store because I believe this is going to demonstrate a new and better way to do pharmacy practice,” said Mohamed Adel Elsabakhawi, the first pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, to operate the platform. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively.”

To view the full press release, visit https://ibn.fm/6iCwu

About Avricore Health Inc.

Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM) (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing…

1 day ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

1 day ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly…

2 days ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent…

3 days ago

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Aligns Manufacturing, Preclinical Work and Clinical Planning for ONC010

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations…

1 week ago